Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of BPX-401 in patients with haematological cancer

Next Previous
Trial Profile

Phase I/II trial of BPX-401 in patients with haematological cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BPX 401 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bellicum Pharmaceuticals

Most Recent Events

  • 12 Mar 2019 According to a Bellicum Pharmaceuticals media release, the company expects to submit an IND application for BPX-603 and to initiate a clinical trial in 2019.
  • 07 Nov 2017 According to a Bellicum Pharmaceuticals media release, the company expects to initiate this trial in the fourth quarter of 2017.
  • 09 May 2016 According to a Bellicum Pharmaceuticals media release, the company plans to initiate the clinical development of BPX-401 in the second half of 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top